She survived by combining Innovative Cancer Treatments for Astrocytoma tumour 结合创新癌症治疗对抗星形胶质瘤

On Temozolomide between 18 Nov 2021 - 29 Dec 2021

A remarkable journey unfolded for an 18-year-old Turkish woman battling an Astrocytoma Grade III with a unique tumour condition. Her story echoes resilience and combining innovative cancer treatment for astrocytoma to overcome medical complexities.

一个非凡的旅程展开在一位18岁的土耳其女孩身上，她正在与分子特异性的III级星形胶质瘤抗争。她的故事彰显了面对医学复杂性时的韧性和创新精神。

Radiotherapy (RT: 60 Gy/30 Fr) and Chemotherapy (Temozolomide 75mg/m2/day) completed in Oct 2021

The timeline narrates a challenging series of treatments. Initially, Temozolomide was administered, accompanied by a blend of radiotherapy and chemotherapy. Despite this concerted effort, the disease defied conventional responses, progressing even after three cycles of Temozolomide. Distressing symptoms emerged, marked by upper right and lower extremity weakness.

The disease progressed even after 3 cycles of temozolomide

治疗时间轴描绘了一系列具有挑战性的治疗过程。最初，她接受了替莫唑胺治疗，辅以放疗和化疗。尽管付出了艰苦努力，但这种疾病却不受传统治疗的影响，在接受了三个替莫唑胺周期后依然在上肢右侧和下肢出现了瘫痪的症状。

The disease progressed even after 3 cycles of temozolomide

Patient was then given second line radiotherapy and has been started on irinotecan (125mg/m2) and bevacizumab (10mg/m2) for 14 days

However, hope rekindled as a second line of defense was initiated. The introduction of irinotecan and bevacizumab marked a pivotal shift in her treatment regimen. Following this, a novel approach emerged with second line radiotherapy SRS and ECCT, a regimen of daily therapy sessions. Encouragingly, after six months, there were promising signs of regression and a positive response to this unconventional strategy.

然而，当第二线治疗方案被启动时，一束希望之光出现了——伊立替康和贝伐单抗的引入标志着她治疗方案的转变。这一转变引发了第二线放疗SRS和ECCT的新思路，即每日治疗方案。令人惊讶的是，在仅仅六个月后，出现了退缩的迹象，证实了这种非传统策略的有效性。

Second line radiotherapy SRS: 5X5 Gy and ECCT was introduced

6 months after: Good response and regression

After 8 months of ECCT

Eight months into the ECCT protocol, the results unveiled an encouraging trend. However, the conclusive moment arrived after 11 months. The MRI results became the beacon of hope – NO PROGRESSION was detected.

在进行了ECCT方案八个月后，出现了令人鼓舞的趋势，然而，这一趋势在十一个月后达到了顶峰。在MRI结果中，一个深刻的启示显现——没有进展，这本身就是一种胜利。

MRI after 11 months of ECCT + beva + irinotecan showed no progression

This journey underscores several crucial insights. The tumor exhibited resistance to conventional radiotherapy and chemotherapy. The strategic introduction of ECCT upon tumor recurrence proved instrumental. The pinnacle achievement lay in the harmonious blend of ECCT, bevacizumab, and irinotecan, a triumphant amalgamation that initially faltered against the temozolomide radio chemotherapy. This saga symbolizes not just resilience but the convergence of medical science and an indomitable spirit, forging new pathways in the battle against adversity.

这一旅程揭示了一些重要的见解。肿瘤对传统放疗和化疗表现出了顽固的抵抗力。在肿瘤复发时战略性地引入ECCT是至关重要的。巅峰成就在于ECCT、贝伐单抗和伊立替康的和谐结合，这一最初对替莫唑胺放疗无效的融合。这个故事不仅象征着韧性，更代表了医学科学与不屈不挠的精神的融合，开辟了在对抗逆境中的新路径。